12 results about "Vitamin K3" patented technology

The invention belongs to the technical field of biological medicines, and discloses application of vitamin K3 in preparation of a medicine for treating psoriasis. The invention finds that the compound vitamin K3 can obviously inhibit the activation of the STING downstream immune pathway and has an inhibition effect on the activation of the STING pathway. A mouse psoriasis model is formulated according to the absorption and metabolism characteristics of the inhibitor VK3, and it is proved that the VK3 can significantly inhibit the process of psoriasis and up-regulation of an STING pathway at an affected part in a transdermal drug delivery mode. The STING pathway does not belong to a main pathway affecting the course of disease in most non-immunodeficient inflammatory diseases, so that a better treatment effect may be generated by using the STING pathway in combination with a direct treatment drug (such as an IL-17A antibody for psoriasis). The vitamin K3 is simple in chemical structure, mature in production process and low in preparation cost, has more remarkable price advantage compared with biological agents and small-molecule targeting drugs, and has high popularization value and application prospects.

The invention relates to the field of nutritional compositions for young animals, such as milk with a high vitamin content for puppies and kittens. More particularly, the invention relates to a method for obtaining a milk-type nutritional composition characterised by a high vitamin K3 content.

The invention discloses a method for improving the synthesis yield of vitamin K3, which comprises the following steps: S1, adding beta-menadione and sodium pyrosulfite into a container, adding ethanol as a solvent, stirring to react for 1-2 hours at the reaction temperature of 30-50 DEG C, heating to 40-70 DEG C, keeping the temperature for 10-60 minutes, and filtering while hot after the reaction is completed to obtain filtrate; and S2, adding sodium pyrosulfite into the filtrate, and then freezing, crystallizing, filtering, washing and drying to obtain a vitamin K3 finished product. When the vitamin K3 is prepared through cooling crystallization, the sodium pyrosulfite is added into the filtrate to be crystallized, so that the crystallization yield of the vitamin K3 can be effectively improved.

The invention discloses a compound immunopotentiator and application thereof in prevention and control of aquatic diseases, and belongs to the technical field of aquaculture. The compound immunopotentiator is prepared by scientifically compounding eucommia ulmoides, astragalus membranaceus, curcumin, vitamin A, vitamin D3, vitamin E and vitamin K3. According to the compound immunopotentiator, through the synergistic effect of the Chinese herbal medicine extract and the compound vitamins, the autoimmunity of aquaculture animal bodies can be remarkably improved, the resistance of the aquaculture animal bodies to pathogenic microorganisms and bad environments is enhanced, the compound immunopotentiator further has a good pathogen removing effect, and damage of pathogens to the aquaculture animals can be effectively reduced. The compound immunopotentiator provided by the invention is used as a combination of a plant-derived drug and multivitamins, has no problems of environmental pollution and drug resistance, and is good in safety and effectiveness.

The invention discloses a formula and a processing method for ecological culture of crustacean aquatic products, and the formula comprises the following medicines by weight: glycine / methionine chelated trace elements: by taking glycine as an example, not less than 13% of magnesium citrate, 9-20 g of magnesium citrate, not less than 21% of zinc glycinate, 5-9.5 g of zinc glycinate, not less than 15% of manganese glycinate, 3.5-6.5 g of manganese glycinate, not less than 15% of copper glycinate, and 1-2.5 g of copper glycinate; 6-11g of ferrous glycinate with the concentration of more than or equal to 17%; the selenium content of the yeast is 2,000 PPM, and is 1-1.5 g; per kilogram of the vitamin compound comprises 550000-8000000 IU of vitamin A, 150000-45000000 IU of vitamin D3, more than or equal to 3500 milligrams of vitamin E, more than or equal to 1200 milligrams of vitamin K3, more than or equal to 800 milligrams of vitamin B1, more than or equal to 5000 milligrams of vitamin B2, more than or equal to 800 milligrams of vitamin B6, more than or equal to 2000 micrograms of vitamin B12 and more than or equal to 15000 milligrams of vitamin C; the invention relates to the technical field of aquaculture, the formula realizes the virtuous cycle of efficient absorption, sedimentation, slow release, decomposition and supply of trace elements through artificial and natural synergistic nutrition chain design, and achieves the ecological breeding target of'zero emission 'of nutrient substances and'zero addition' of chemical agents.

The application is a method for quantitatively detecting vitamin K3, characterized in that: a "HCHO NaHSO3-Na2SO3" pH clock reaction system is used as a detection solution, and different responses of the system to different concentrations of vitamin K3, namely different induction times, are used to realize quantitative analysis of vitamin K3. The quantitative analysis method for vitamin K3 disclosed by the application has the characteristics of high accuracy, easy operation, and convenience and rapidness.

The invention discloses a pharmaceutical composition for resisting NQO1 high-expression malignant tumors and application of the pharmaceutical composition, and relates to the technical field of medicines. When the vitamin K3, the vitamin K4 or the pharmaceutically acceptable salts thereof are combined with the quinone compounds for use, the killing sensitivity of NQO1 high-expression malignant tumor cells to the quinone compounds is obviously enhanced, and an explosive synergistic or synergistic anti-tumor effect is initiated; the killing effect of various quinone compounds on NQO1 high-expression malignant tumor cells is remarkably improved, so that the application dosage of the quinone compounds is reduced to reduce side effects, and the effect of killing NQO1 high-expression tumor cells with low dosage and high efficiency is achieved.

The invention discloses application of a combination of a copper ion carrier ilisemox carrying copper ions and vitamin K3 in preparation of a medicine for treating liver cancer. Through high-throughput screening of metabolites having a synergistic effect with copper death (copper ion carrier ES combined with copper ions), preliminary screening shows that vitamin K3 can cooperatively kill liver cancer cells with ES + Cu < 2 + >, and further in-vivo and in-vitro various experiments prove that vitamin K3 can obviously promote liver cancer cell copper death, so that the vitamin K3 can obviously promote liver cancer cell copper death. Vitamin K3 and ES + Cu < 2 + > are combined for use, so that liver cancer can be effectively inhibited, and a remarkable synergistic killing effect on liver cancer is achieved. Therefore, the invention provides a strategy for synergistically treating the liver cancer by jointly using the vitamin K3 and the ES + Cu < 2 + >, and the strategy can be used for manufacturing liver cancer biological medicines, liver cancer chemical medicine raw material medicines and preparations.

The application discloses application of an E3 ubiquitin ligase SIAH2 inhibitor in preparation of a lupus nephritis kidney protection drug. Researches of the application show that the SIAH2-LATS2 axis participates in the pathogenic process of kidney fibrosis of lupus nephritis, and it is confirmed that LATS2 can be used as a target point for preventing fibrosis progression in lupus nephritis. It is shown that LATS2 is abnormally down-regulated in lupus nephritis, and the use of an E3 ubiquitin ligase SIAH2 inhibitor can restore the LATS2 level, reduce the production of a LATS2 downstream gene CTGF, reduce the occurrence of interstitial fibrosis, reduce the proteinuria effect of lupus nephritis, thereby protecting the kidney function and delaying the progression of lupus nephritis. The application uses the SIAH2 inhibitor vitamin K3, which can prevent the conversion of lupus nephritis to ESRD, and can be used as an effective drug for treating and preventing kidney fibrosis, and provides a new selection for lupus nephritis treatment drugs and fibrosis prevention and treatment drugs.

To provide a vitamin D eutectic crystal excellent in chemical stability, a method for preparing the same, and applications thereof.SOLUTION: Vitamin D and a eutectic ligand are comprised, wherein the Vitamin D is vitamin D2 or vitamin D3, and the eutectic ligand is idebenone or vitamin K3. The vitamin D cocrystal according to the present invention not only can significantly improve the chemical stability of vitamin D under light and heat conditions, but also can avoid the problems caused by physically mixing vitamin D with other APIs.SELECTED DRAWING: Figure 1

The invention discloses a method for synthesizing high-value chemicals through enzyme catalysis aromatic hydrocarbon dearomatization. According to the method, in a water phase system, 2-methylnaphthalene is taken as a substrate, hydrogen peroxide is taken as an oxidant, ascorbic acid is taken as a free radical scavenger, and a non-specific peroxygenase mutant is taken as a catalyst, so that an efficient catalytic synthesis way is established. The non-specific peroxygenase mutant is obtained by carrying out rational design modification on the non-specific peroxygenase, including mutation on a 99th or 119th amino acid residue point or truncation on a C terminal, so that the tolerance and catalytic efficiency of the enzyme to a high-concentration aromatic hydrocarbon substrate are improved. Efficient synthesis of menadione can be achieved through a green and mild biological enzyme method, and a key enzyme tool is provided for industrial biological manufacturing of vitamin K3.

The utility model discloses an oxidation liquid preparation device for vitamin K3 production, which comprises an oxidation liquid preparation device main body, the oxidation liquid preparation device main body comprises a liquid preparation stirring tank, a liquid preparation stirrer is arranged in the middle of the interior of the liquid preparation stirring tank, and quantitative liquid preparation cylinders are mounted at two ends of the upper surface of the liquid preparation stirring tank; by designing a uniform mixing liquid preparation mechanism, when an oxidation liquid preparation device main body is used for preparing liquid and a liquid preparation stirrer is used for stirring and mixing at the middle position in a liquid preparation stirring tank, a motor is electrified to operate to drive a driving gear to rotate, and the driving gear is meshed with the outer surface of a gear ring to drive the gear ring to rotate when rotating; when the gear ring rotates, the connecting rod and the mounting plate are driven to rotate stably, and the mounting plate drives the connecting shaft and the mixing rod to rotate at the edge of the inner surface of the prepared liquid stirring tank for mixing treatment, so that the prepared liquid is uniformly mixed and stirred in the prepared liquid stirring tank, and the prepared liquid is more uniform.